Webinar: One-on-One with Cyagen's Animal Model Experts

On behalf of our animal model experts, we invite you to request a Cyagen One-on-One Webinar!

Animal modeling has a played a prominent role in traditional scientific research for hundreds of years, and more recently, inbred strains have been developed to support genetically modified models for applications in biomedical and health research. Additionally, gene-edited animal models are widely adopted by drug R&D companies, scientific research institutions, and laboratories worldwide in analyzing the function of disease-related genes, studying signaling pathways, identifying drug targets, screening new drugs, and more.

With these webinar opportunities, Cyagen’s expert team will comprehensively explain the cutting-edge technology, academic hotspots, and application limitations of animal models - such as genetically modified, humanized, and immunodeficient mice - from various perspectives, as we aim to exchange and share valuable experiences with you and your team.

If you would like to request a specific topic for our Webinar series, please fill out the form and we will contact you to arrange the details.

Cyagen’s Animal Model Experts and Main Lecture Themes

Theme 1

Applications of Genetically Modified Mice in Translational Medicine

Main Topics

● Strategies and methods of different gene-editing technologies
● The application of humanized mouse models in drug discovery
● In-depth explanation of the animal models in hot research areas - Immunity, Cardiovascular, Tumor, Metabolism, Nerve
● AlphaKnockout gene-targeting system and corresponding AI Knockout Mouse Model eBank
● Applications of germ-free mice in the interconnected mechanisms of gut microbes and immunity
Lecturer
Dr. Steve Yu Senior Vice President and Senior Scientist
Dr. Steve Yu has more than 20 years of experience in the field of genetically modified animal models from both R&D and management roles. As an internationally renowned expert in model animals and cell biology, Dr. Yu successively served in Yale School of Medicine and NYU Grossman School of Medicine, inGenious Targeting Laboratory (iTL), Applied StemCell (ASC) and other institutions in the field of genetically modified animal models. Currently, Dr. Yu is working for Cyagen as Senior Vice President and Senior Scientist, primarily responsible for the technical development of genetically modified animal model platforms. His research results have been published in high-impact journals such as Nat Immunol and Mol Cell Biol.

Theme 2

Overview of Cyagen Small Animal Surgical & Disease Model Services - From Gene to Phenotype

Main Content

● Translating drug discovery to clinical applications: how to cross the valley of death?
● How to prepare complex and elaborate small animal disease models:
1. Model of Myocardial Ischemia/Reperfusion Injury 2. Pulmonary Hypertension (PHTN) Model and Hemodynamics Test 3. Embolic Middle Cerebral Artery Occlusion (MCAO) 4. Transverse Aortic Constriction (TAC) 5. Acute Kidney Injury (AKI) 6. Digestive Surgery
● Experience and case analysis
Lecturer
Dr. Rongli Zhang Chief Scientist of Cyagen Surgical Disease Models
Dr. Rongli Zhang has more than 20 years of experience in creating mouse surgical models. Prior to Cyagen, Dr. Zhang was employed by China Academy of Chinese Medical Science (CACMS), Tsinghua University (THU), Peking University (PKU) and other internationally renowned academic institutions after earning his PhD. Since 2011, he has worked in Case Western Reserve University in the U.S. as both a research scientist and as director of the Cardiovascular Physiology Laboratory, where he leads the discovery of disease phenotypes in genetically engineered animals and preclinical drug development. In addition, he has done many preclinical pharmacology studies for domestic and worldwide pharmaceutical enterprises - helping these companies achieve successful product launches. Dr. Zhang has finished 10 projects during his work in China and took part in multiple fund programs in the U.S. supported by both the NIH (National Institutes of Health) and AHA (American Heart Association). He has 60 publications in SCI journals, with many articles published in high-impact academic journals (such as Nature, Proceedings of the National Academy of Sciences, Journal of Clinical Investigation, Circulation, Cell, Nature Communications, and Science Translational Medicine).

About Cyagen

As a global leader in animal model services, Cyagen provides major gene knockout (KO), gene knockin (KI), conditional knockout (cKO), humanization, and other model customization services in superior quality and full guarantee. Additionally, Cyagen has established its self-developed pharmaceutical R&D lines - catering to drug development and screening in the field of cancer, immunity, endocrine system, cardiovascular system, infectious diseases, and more. In the spirit of continual progress, the company has also built several new platforms for antibody drug development on the basis of humanized mouse antibodies, Germ-free (GF) based microbial drug R&D technology, and mouse phenotype analysis. Cyagen’s products and services have been cited in over 3,600 papers cross highly reputed publications and journals including Cell, Nature, Science and more - all in under 15 years.